U.S. microarray market highlights

The U.S. microarray market generated a revenue of USD 2,650.5 million in 2024 and is expected to reach USD 3,493.4 million by 2030.
The U.S. market is expected to grow at a CAGR of 4.9% from 2025 to 2030.
In terms of segment, consumables was the largest revenue generating product and services in 2024.
Instruments is the most lucrative product and services segment registering the fastest growth during the forecast period.

Microarray market data book summary

Market revenue in 2024	USD 2,650.5 million
Market revenue in 2030	USD 3,493.4 million
Growth rate	4.9% (CAGR from 2025 to 2030)
Largest segment	Consumables
Fastest growing segment	Instruments
Historical data	2018 - 2023
Base year	2024
Forecast period	2025 - 2030
Quantitative units	Revenue in USD million
Market segmentation	Consumables, Instruments, Software and Services

Other key industry trends

In terms of revenue, U.S. accounted for 42.6% of the global microarray market in 2024.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
In North America, U.S. microarray market is projected to lead the regional market in terms of revenue in 2030.
Canada is the fastest growing regional market in North America and is projected to reach USD 322.1 million by 2030.

The U.S. leads the microarray market, driven by Key drivers include extensive R&D investments, a well-established academic and clinical research environment, and strong funding support from institutions like the National Institutes of Health (NIH). The integration of microarrays in genomic studies, cancer diagnostics, and pharmacogenomics is gaining traction, especially in personalized medicine.

Recent developments include collaborations between academic institutions and biotech companies aimed at advancing high-density DNA microarrays and protein microarrays. Furthermore, the presence of leading players such as Thermo Fisher Scientific and Agilent Technologies reinforces innovation in microarray platforms and consumables.

In April 2025, AliveDx announced that it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for its MosaiQ Autoimmune Plex (AIPlex) Connective Tissue Diseases (CTDplus) Multiplex Microarray.

U.S. Microarray Market Size & Outlook, 2025-2030

Data Tree